PathoFinder

PathoFinder is a privately held Dutch diagnostics company founded in 2004 (operationally noted as 2010) that has established itself in the syndromic molecular testing market. It leverages proprietary multiplex PCR technologies, primarily its 2SmartFinder® platform, to detect up to 24 pathogens in a single assay, aiming to improve patient outcomes through rapid, comprehensive infectious disease diagnostics. The company is commercial-stage, with a portfolio of CE-marked IVD kits distributed globally, and maintains ISO 13485:2016 and IVDR certifications. Its strategy focuses on expanding its assay menu, particularly in fungal diagnostics, and transitioning to automated platforms to solidify market leadership.

Proprietary multiplex PCR technologies: 1) 2SmartFinder® for single-tube, real-time detection of up to 24 pathogens via melting curve analysis and universal primers. 2) RealAccurate® for quadruplex real-time PCR assays.

PathoFinder competes in the multiplex molecular diagnostics market against major players like BioMérieux (BioFire FilmArray), Luminex (xTAG, ARIES), Qiagen, and Roche. Its differentiation lies in the high-plex capability of its 2SmartFinder® technology, but it lacks the fully integrated, automated sample-to-answer systems offered by some competitors, which is a key focus of its development strategy.